Welcome to our dedicated page for Ideaya Biosciences SEC filings (Ticker: IDYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Overview of IDEAYA Biosciences
IDEAYA Biosciences Inc. (IDYA) is a precision medicine oncology company that specializes in discovering and developing targeted therapeutics for genetically defined patient populations. By leveraging advanced molecular diagnostics and synthetic lethality, the company identifies cancer vulnerabilities and develops small molecule therapies aimed at interfering with DNA damage repair and tumor microenvironment interactions. IDEAYA operates at the intersection of drug discovery and translational biomarker validation, positioning itself as a key entity in the evolving field of precision medicine.
Core Business Areas and Approach
IDEAYA’s core business is built on its unique approach to oncology drug discovery. The company focuses on:
- Synthetic Lethality: Exploiting vulnerabilities in the DNA damage and repair mechanisms specific to certain tumor genotypes, thereby enabling targeted therapeutic interventions.
- Precision Medicine: Utilizing molecular diagnostics and translational biomarkers to select patients most likely to benefit from its therapies, ensuring personalized treatment strategies.
- Innovative Drug Discovery: Integrating small molecule discovery with advanced computational methodologies and physics-based approaches to unravel previously undruggable targets.
Market Position and Differentiation
IDEAYA stands out in the competitive oncology landscape due to its robust drug discovery process and its strategic focus on precision therapies. The company has assembled a world-class team of scientists and advisors, including Nobel laureates and national academy members, which underscores its deep expertise and authority in the biotech industry. Furthermore, its collaborations with industry giants and academic partners boost its R&D capabilities and enhance its credibility in developing transformative therapeutic candidates.
Clinical Pipeline and Strategic Collaborations
IDEAYA’s extensive clinical-stage pipeline addresses multiple oncology targets using innovative mechanisms. Its product candidates are designed to exploit synthetic lethality in various biomarker-defined patient groups. The company is actively advancing candidates that target key proteins and enzymes involved in tumor DNA repair and epigenetic regulation. Strategic collaborations with leading pharmaceutical companies not only share the risk and cost of development but also provide access to advanced research and regulatory expertise.
Scientific and Operational Excellence
Backed by a solid foundation of scientific research and rigorous due diligence during drug development, IDEAYA demonstrates a commitment to operational excellence. Its integrated approach couples pioneering laboratory research with state-of-the-art computational methods, ensuring that its innovative candidates are robustly validated preclinically before entering clinical trials. This methodical process helps build trust among stakeholders and supports its long-term potential as an innovator in precision oncology.
Implications in Precision Oncology
Through its focus on genetically defined patient populations, IDEAYA addresses an unmet need in the treatment of cancers with specific molecular profiles. Investors, analysts, and industry experts find value in understanding how the company’s unique focus on synthetic lethality and translational biomarker development may offer differentiated outcomes compared to traditional approaches. The company’s rigorous, data-driven methodology provides clear insights into the complex dynamics of oncogenic pathways, reinforcing its reputation as a knowledgeable and respected player in the biotech community.
Conclusion
In summary, IDEAYA Biosciences exemplifies a next-generation precision medicine approach in oncology. With its strategically developed pipeline, strong scientific foundation, and collaborative industry partnerships, the company is well positioned to contribute meaningfully to advancements in targeted cancer therapeutics, fostering better patient outcomes through innovative science and technology.
IDEAYA Biosciences (Nasdaq: IDYA) filed an 8-K disclosing a material C-suite change. On June 26 2025, the Board appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer under Item 5.02. The filing states the appointment is effective immediately and made pursuant to Section 16(a)-1(f) of the Exchange Act.
No resignations, compensation terms, financial guidance or other business updates were provided. Investors should monitor upcoming filings for any strategic or financial initiatives led by the new CFO.
IDEAYA Biosciences (IDYA) director Wendy L. Yarno received a stock option grant for 20,000 shares of common stock on June 24, 2025. The options were granted with an exercise price of $21.78 per share and will expire on June 24, 2035.
Key terms of the option grant:
- Vesting occurs at the earlier of: (1) first anniversary of grant date or (2) immediately before the next Annual Meeting
- Vesting is contingent on continued Board service
- The options represent a direct ownership form
This Form 4 filing was submitted by Andres Ruiz Briseno as attorney-in-fact for Yarno on June 26, 2025, meeting the SEC's two-day reporting requirement for insider transactions.
IDEAYA Biosciences (IDYA) Director Jeffrey Stein received a new stock option grant on June 24, 2025. The grant consists of 20,000 stock options with an exercise price of $21.78 per share.
Key details of the option grant:
- Expiration date: June 24, 2035
- Vesting schedule: 100% vests on earlier of (i) first anniversary of grant date or (ii) immediately before next Annual Meeting
- Vesting contingent on continued Board service
This Form 4 filing, signed by Attorney-in-Fact Andres Ruiz Briseno on June 26, 2025, represents standard equity compensation for non-employee director service. The grant aligns the director's interests with shareholders through long-term equity ownership.
IDEAYA Biosciences (IDYA) director Malcolm Garret Hampton received a new stock option grant on June 24, 2025. The grant consists of:
- Options to purchase 20,000 shares of common stock
- Exercise price set at $21.78 per share
- Expiration date of June 24, 2035
The options feature an accelerated vesting schedule, with 100% vesting occurring at the earlier of: (1) the first anniversary of the grant date, or (2) immediately before the next Annual Meeting, contingent on Hampton's continued board service. This grant appears to be part of the company's standard director compensation program. The transaction was reported via Form 4 filed by Hampton's attorney-in-fact, Andres Ruiz Briseno.
IDEAYA Biosciences (IDYA) director Terry J. Rosen received a stock option grant on June 24, 2025. The key details of this insider transaction include:
- Granted 20,000 stock options to purchase common stock at an exercise price of $21.78 per share
- Options will expire on June 24, 2035
- Vesting schedule: 100% vests on the earlier of: - First anniversary of grant date - Immediately before next Annual Meeting
- Vesting is contingent on continued board service
This grant represents standard non-employee director compensation and aligns the director's interests with shareholders through long-term equity ownership. The filing was submitted via attorney-in-fact Andres Ruiz Briseno on June 26, 2025.
IDEAYA Biosciences held its 2025 Annual Meeting of Stockholders on June 24, 2025, where shareholders voted on three key proposals:
- Director Elections: Jeffrey L. Stein, Ph.D. was elected with strong support (69,077,770 votes for), while Scott W. Morrison received more divided support (42,132,938 votes for, 34,900,780 withheld)
- Auditor Ratification: PricewaterhouseCoopers LLP was approved as the independent auditor for FY2025 with overwhelming support (79,645,454 votes for)
- Executive Compensation: The non-binding advisory vote on executive compensation passed but showed significant dissent (59,798,805 for vs 17,040,207 against)
Out of 87,577,550 total outstanding shares eligible to vote, the meeting saw substantial shareholder participation. The split vote on Morrison's directorship and significant opposition to executive compensation suggests some shareholder concerns about governance and compensation practices.
FAQ
What is the current stock price of Ideaya Biosciences (IDYA)?
What is the market cap of Ideaya Biosciences (IDYA)?
What is the primary focus of IDEAYA Biosciences?
How does IDEAYA differentiate itself in the oncology market?
Which innovative approaches does IDEAYA employ in its drug development?
What types of diseases are targeted by IDEAYA's therapeutics?
How does IDEAYA ensure that its therapies reach the right patient populations?
What role do strategic partnerships play for IDEAYA?
Can you explain the term 'synthetic lethality' in the context of IDEAYA's work?
How does IDEAYA contribute to advancements in precision oncology?
